Hematology/Oncology

Top Story

Adjuvant ovarian function suppression in young women

July 26, 2017

Adjuvant ovarian function suppression with either tamoxifen or exemestane significantly improved the breast cancer–free interval in young women with hormone receptor–positive breast cancer, study data showed.

“Women younger than 35 years with breast cancer have historically had poor outcomes, with increased rates of both local and distant recurrence,” Gini F. Fleming, MD, he University of Chicago, and colleagues wrote. “Although women younger than 35 years have higher rates of triple-negative breast cancer, it is paradoxically in the hormone receptor-positive subgroup that the most significantly worse outcomes have been observed.”

FDA News

FDA grants fast track designation to caplacizumab for rare blood disorder

July 26, 2017
The FDA granted fast track designation to caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura, according to the drug’s manufacturer…
Supplement

Meeting Update: Clinicians discuss findings, practice implications from ASCO Annual Meeting

HemOnc Today, July 25, 2017
The ASCO Annual Meeting, held this year in Chicago from June 2-6 under the theme “Making a difference in cancer care with you,” brought together…
Point/Counter

Should an independent regulatory body oversee the FDA drug approval process?

HemOnc Today, July 25, 2017
POINT Having worked in drug development for 2 decades, including serving as an FDA medical officer/senior medical analyst, I can say with conviction that the FDA mostly does…

Oncology leaders: Biden Cancer Initiative will continue moonshot’s momentum

HemOnc Today, July 25, 2017
The Biden Cancer Initiative — launched in June by former Vice President Joe Biden and his wife, Jill Biden, PhD — will continue to promote the collaboration…
More Headlines »
CME

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

This activity is supported by an independent educational grant from Incyte Corporation.

Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to…
More »
Video
Meeting News

VIDEO: Adam Brufsky, MD, PhD, discusses results of MONARCH-2, PALOMA-1 trials

June 23, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement